Table 3.
Comparison of clinical parameters between the patients with a NLR of <3.0 and ≥3.0 (CSS cut-off)
| NLR <3.0 (n=31) | NLR ≥3.0 (n=22) | p | |
|---|---|---|---|
| Age, years, Mean±SD | 37.97±15.5 | 40.1±16.2 | 0.632 |
| Tumor size, cm, Mean±SD | 4.38±2.37 | 4.60±2.03 | 0.734 |
| Follow-up time, months, Mean±SD | 23.42±17.76 | 23.73±18.89 | 0.952 |
| Rete testis invasion, n (%) | 1 (3.2) | 1 (4.5) | 0.062 |
| Lymphovascular invasion, n (%) | 3 (9.7) | - | |
| Stage, n (%) | 0.753 | ||
| 1 | 16 (51.6) | 12 (54.5) | |
| 2A | 8 (25.8) | 3 (13.6) | |
| 2B | 3 (9.7) | 2 (9.1) | |
| 2C | 3 (9.7) | 3 (13.6) | |
| 3 | 0 | 0 | |
| 4 | 1 (3.2) | 2 (9.1) | |
| Lymph node metastasis at the time of diagnosis, n (%) | 14 (45.2) | 10 (45.5) | 0.983 |
| Lung metastasis at the time of diagnosis, n (%) | 3 (9.7) | 3 (13.6) | 0.683 |
| Progression, n (%) | 2 (6.5) | 3 (13.6) | 0.638 |
| Time to progression, months, mean±SD | 15.0±6.97 | 22.0±12.51 | 0.737 |
| Cancer specific death, n (%) | 2 (6.5) | 5 (22.7) | 0.113 |
CSS: cancer specific survival; NLR: neutrophil-to-lymphocyte ratio; SD: standard deviation